Drug profile

The FDA adverse-event record for Praziquantel; Moxidectin

169 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Praziquantel; Moxidectin. See the species affected, top reactions, and outcomes below.

169
adverse-event reports
7.7%
death-coded share
Horse
most-reported species
25
Colic - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
169
Total Reports
13
Deaths Reported
7.7%
Death Rate

Active Ingredients

Praziquantel; Moxidectin

Administration Routes

OralUnknownTopicalIntraocular

Species Affected

Horse 115
Unknown 35
Dog 15
Human 2
Fish 1
Cat 1

Most Affected Breeds

Unknown 37
Quarter Horse 30
Horse (unknown) 26
Thoroughbred 14
Paint 8
Arab 6
Tennessee Walking Horse 5
Crossbred Equine/horse 3
Mustang 3
Miniature 2

Most Reported Reactions

Colic 25
Lack of efficacy - NOS 18
Ataxia 13
Lethargy (see also Central nervous system depression in 'Neurological') 12
No sign 12
Product syringe issue 11
Fever 11
Difficulty of Use 11
Depression 8
Death by euthanasia 8
INEFFECTIVE, PINWORMS 7
Behavioural disorder NOS 7

Outcome Breakdown

Recovered/Normal
57 (42.5%)
Outcome Unknown
38 (28.4%)
Ongoing
24 (17.9%)
Euthanized
7 (5.2%)
Died
6 (4.5%)
Recovered with Sequela
2 (1.5%)

Praziquantel; Moxidectin Adverse Event Insights

169 reports name Praziquantel; Moxidectin; 13 recorded a death outcome (7.7% of reported events, not a population-level mortality rate). Active ingredient: Praziquantel; Moxidectin. Administration routes: Oral, Unknown, Topical, Intraocular.

By species: Horse (115 reports), Unknown (35 reports), Dog (15 reports). By breed: Unknown (37), Quarter Horse (30), Horse (unknown) (26).

Leading clinical signs: Colic (25), Lack of efficacy - NOS (18), Ataxia (13), Lethargy (see also Central nervous system depression in 'Neurological') (12). Outcome, 134 coded reports: Recovered/Normal leads at 42.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.